SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
|
|
- Sara Flowers
- 5 years ago
- Views:
Transcription
1 SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen The Netherlands
2 Disclosures Research Support Abbvie, AstraZeneca, Boehringer Ingelheim, Janssen Consultancy Abbvie, Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius, Gilead, Janssen, Merck, Mitsubishi Pharma.
3 Objectives Review results of recent outcome trials with SGLT2 inhibitors Summarize effects of SGLT2 inhibitors in Diabetic Kidney Disease Review mechanisms and effects of SGLT2 inhibitors on renal outcomes Discuss the potential role of SGLT2 inhibitors in non-diabetic kidney disease Summarize the position of SGLT2 inhibitors in context of other glucose lowering agents
4 The sodium glucose mechanism in the proximal tubule ~6 g/day (24kCal) ~25 mmol/day Heerspink / Cherney Circulation (1):752-72
5 Cardiovascular outcomes with SGLT-2 inhibitors Patients with event/analysed SGLT-2 Placebo HR (95% CI) p-value EMPAREG 49/ / (.74,.99) <.1 (non-inferiority).4 (superiority) CANVAS 585/ / (.75,.97) <.1 (non-inferiority).2 (superiority) DECLARE 756/ / (.84, 1.3) <.1 (non-inferiority) P=.17 (superiority) Hazard Ratio (95%CI) Zinman B et.al. NEJM 216; Neal B. et.al. NEJM 217; Wiviott S et.al. NEJM 218
6 Cumulative probability of event (%) Patients with an event (%) Kidney outcomes in SGLT-2 inhibitor trials EMPA-REG CANVAS DECLARE HR.54 (95% CI.4,.75) Placebo Empagliflozin Hazard ratio.6 (95% CI, ) Placebo Canagliflozin Hazard ratio.76 (95% CI, ) Placebo Dapagliflozin Months since randomization Years since randomisation egfr (ml/min/1.73m 2 ): UACR (mg/g): Wanner C et.al. NEJM 216; Neal B. et.al. NEJM 217; Wiviott S et.al. NEJM 218
7 Summary of Product Characteristics Dapagliflozin Canagliflozin Empagliflozin
8 Glycemic effects of dapagliflozin is blunted in patients with renal impairment Placebo-adjusted change from baseline over time with dapagliflozin in HbA1c in the overall population egfr 45-6 ml/min/1.73m 2 egfr 6-9 ml/min/1.73m 2 egfr >9 ml/min/1.73m 2 Excludes data after rescue. Adj., adjusted; BL, baseline; CI, confidence interval. Petrykiv S, et al. Clin J American Soc Nephrol 217;12:
9 UACR, % (95% CI) Albuminuria lowering effect of dapagliflozin persists in patients with renal impairment UACR, mg/g (95% CI) No renal impairment or CKD stage 1 3A 1a CKD stage 3B 4 2b egfr sub-group BL <9 45 < BL Placebo DAPA 1 mg DAPA 5 mg Study week Study week UACR 3 mg/g at baseline a CKD stage 1 3A defined as egfr 9 <6; b CKD stage 3B 4 defined as egfr 15 <45 CI, confidence interval; CKD, chronic kidney disease; DAPA, dapagliflozin; PBO, placebo; UACR, urine albumin:creatinine ratio 1. Petrykiv S, et al. Clin J American Soc Nephrol 217;12: ; 2. Dekkers CCJ, et al. Nephrol Dial Transplant 218 [Epub ahead of print]
10 Adjusted mean change from baseline in HbA 1c, % (95% CI) Dapagliflozin maintains modest Hba1c lowering efficacy in CKD stage 3 Adjusted mean change from baseline in egfr, ml/min/1.73 m 2 (95% CI) Treatment with dapagliflozin over 24 weeks significantly improved glycemic control, body weight, and systolic blood pressure in patients with T2DM and CKD stage 3A a, with no reduction in egfr 4 HbA 1c Dapagliflozin 1 mg (n=159) Placebo (n=161) 4 3 egfr Dapagliflozin 1 mg (n=16) Placebo (n=161) Follow-up period Time (weeks) Time (weeks) a egfr: ml/min/1.73 m 2 CKD, chronic kidney disease; CI, confidence interval; egfr, estimated glomerular filtration rate; HbA 1c, glycated hemoglobin; T2DM, Type 2 diabetes mellitus Fioretto P, et al. Diabetes Obes Metab 218 [Epub ahead of print]
11 Alterations in proximal sodium reabsorption modulate TGF Normal TGF Impaired TGF Restored TGF 3 Appropriate afferent arteriole tone Normal GFR Macula densa Afferent arteriole vasodilation Elevated GFR Decreased Na + delivery to macula densa 4 Afferent arteriole constriction 5 Normalization of GFR Increased Na + delivery to macula densa Na + /glucose reabsorption Increased Na + /glucose reabsorption Na + 2 SGLT2 SGLT2 1 Na + SGLT2 inhibition in proximal tubule Glucosuria Normal physiology Hyperfiltration a in early stages of diabetic nephropathy SGLT2 inhibition reduces hyperfiltration via TGF a Renal hyperfiltration: GFR 135 ml/min/1.73 m 2 GFR, glomerular filtration rate; SGLT2, sodium glucose co-transporter 2; TGF, tubuloglomerular feedback Cherney D, et al. Circulation 214;129:
12 Mean RBV (ml/min/1.73 m 2 ) Mean GFR (ml/min/1.73 m 2 ) Mean GFR (ml/min/1.73m2) SGLT2 inhibitors decrease RPF and GFR Type 1 diabetes Type 2 diabetes Baseline 2 2 SGLT2 inhibition RBF T1D-H (Euglycemia) 6 baseline week 12 Cherney D et al. Circulation 214:129; Heerspink et.al. Diab Obes Metab 213: 15:853-62
13 Mechanism of action of SGLT2 inhibitors and other antihypertensive agents Rajasekeran et.al. Current Opinon Nephrology Hypertension 217
14 Acetozolamide (proximal diuretic) decreases RBF and GFR in obese non-diabetic individuals Acetazolamide increases urinary sodium excretion and decreases GFR/ERPF Furosemide does not activate tubulo-glomerular feedback as it blocks sodium transport into the macula densa Zingerman Plos One 214
15 Adjusted mean egfr (ml/min/1.73 m 2 ) Adjusted mean egfr (ml/min/1.73 m 2 ) CANVAS: Canagliflozin attenuates egfr decline CANVAS Patients, n PBO CANA PBO Baseline 18/ CANA Weeks since randomization CANVAS-R Patients, n PBO CANA PBO Baseline days CANA Weeks since randomization off-treatment CANA, canagliflozin; egfr, estimated glomerular filtration rate; PBO, placebo. Perkovic V. et.al. Lancet D&E 218
16 CREDENCE stopped early for overwhelming efficacy
17 Intraglomerular Hypertension is a common feature and driver of disease progression in chronic kidney disease Hypertensive nephrosclerosis Arterial stiffening Renal plasma flow Intraglomerular hypertension Glomerular hyperfiltration Diabetic nephropathy Whole kidney RBF FF Vasodilation of afferent arteriole Proximal tubular sodium reabsorption and glomerular hypertension RAAS Obesity-induced CKD Renal plasma flow GFR with resulting FF Caloric restriction has been shown to reverse glomerular hyperfiltration Focal segmental glomerulosclerosis Single-nephron level; plasma flow per nephron Intrarenal vasodilation and glomerular hypertension CKD, chronic kidney disease; FF, filtration fraction; GFR, glomerular filtration rate; RAAS, renin angiotensin aldosterone system; RBF, renal blood flow
18 Body weight change (%) Canagliflozin lowers body weight and CV risk factors in obese nondiabetic individuals (N=376) Systolic BP change (mmhg) Uric Acid change (umol/l) egfr change f(ml/min/1.73m2). Body Weight Systolic BP Uric Acid egfr Placebo Placebo Placebo Placebo Not reported Bays et.al. Obesity 214;14:
19 DAPA-CKD and EMPA-KIDNEY: SGLT2 inhibition in patients with diabetic and non-diabetic CKD Randomization 1:1 Randomization 1:1 DAPA-CKD Population: Patients with CKD stage 2 4 (egfr ml/min/1.73m 2 ) UACR 2 mg/g Stable ACE inhibitor / ARB Placebo + SoC Dapagliflozin 1 mg + SoC Primary endpoint: Time to composite of 5% sustained decline in egfr, onset of ESRD, CV, or renal death Anticipated targets 4 patients Event-driven Duration 45 months EMPA-KIDNEY Population: Patients with CKD stage 2 4 (egfr 2 9 ml/min/1.73m 2 ) Placebo + SoC UACR 3 mg/g if egr>45 ml/min Stable ACE inhibitor / ARB Empagliflozin + SoC Primary endpoint: Time to composite of 4% egfr decline, onset of ESRD, CV, or renal death Anticipated targets 5 patients Event-driven Duration 54 months ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CV, cardiovascular; egfr, estimated glomerular filtration rate; ESRD, end-stage renal disease; hhf, hospitalized heart failure; SoC, standard of care; T2DM, Type 2 diabetes mellitus; UACR, urine albumin:creatinine ratio
20 EASD Guideline
21 RAAS and SGLT2 inhibitors reduce intraglomerular pressure through different mechanisms SGLT2i tubuloglomerular feedback, afferent arteriole tone and intraglomerular pressure ACEi and ARB efferent arteriole tone and intraglomerular pressure Initial in egfr followed by stabilization albuminuria Initial in egfr followed by stabilization albuminuria Renal Protection (to be determined) Renal Protection Perkovic et.al. Cur Med Res Opin 215:31; Increased intraglomerular pressure and hyperfiltration are key steps in the progression of diabetic kidney disease
22 Cumulative probability of event (%) EMPAREG: Empagliflozin reduces risk of AKI Empagliflozin had a protective effect against acute renal failure and acute kidney failure vs placebo Empagliflozin Placebo 1 Acute renal failure 5 Acute kidney injury No. of patients Acute renal failure Empagliflozin Placebo Acute kidney injury Empagliflozin Placebo Months CI, confidence interval; HR, hazard ratio; Wanner C, et al. N Engl J Med. 216 Jul 28;375(4):323-34
23 AKI is less frequently observed during SGLT2 inhibition in two large contemporary cohorts of two major US health systems User (n=372) Mount Sinai cohort Nonuser (n=372) P1 User (n=1,27) Geisinger cohort Nonuser (n=1,27) P2 Mount Sinai (unadjusted) AKI KDIGO -inpatient 14 (3.8) 36 (9.7).2 26 (2.2) 55 (4.6).1 AKI ICD 22 (5.9) 4 (1.8).2 15 (1.2) 36 (3.).3 Peak creatinine in AKI KDIGO events Change in serum creatinine during AKI KDIGO events Need for acute dialysis 1.6 ( ) 1.9 ( ) ( ) 1.6 ( ).91.5 (.4.7).9 (.8 1.3).4.6 (.5 1.).6 (.4 1.2).8 1 (.3) 1 (.3) 1. (.) 1 (.1).317 P1 and P2 are P values for primary and secondary analyses, respectively. Mount Sinai (adjusted) Geisinger (unadjusted) Geisinger (adjusted) Hazard ratio (95% confidence interval) Mount Sinai Geisinger AKI, acute kidney injury; SGLT2, sodium glucose co-transporter 2; US, United States. Nadkarni et al. Diabetes Care 217 4:
24 Summary Recent outcome trials with SGLT2 inhibitors confirmed the CV safety and efficacy of these agents (particular protection for Heart Failure and Kidney Failure protection) Hba1c lowering effects attenuated in Diabetic Kidney Disease but other effects persists CREDENCE trial in Diabetic Kidney Disease prematurely stopped for overwhelming efficacy Benefits of SGLT-2 inhibitors mediated by: Diuresis / Natriuresis Activation Tubulo-Glomerular Feedback Reducing intra-renal hypoxia? Given that effects of SGLT2 inhibitors are unlikely mediated by glycemic improvements and SGLT-2 inhibitors can be safely used without inducing hypoglycmemica current trials examine the efficacy in non-diabetic kidney diseases Guidelines recommend SGLT-2 inhibitors as second line treatment (adjunct to metformin) in indivduals with diabetes and CKD
Managing patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationSGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney?
SGLT2-inhibition: A New Strategy to Protect the Heart and the Kidney? Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen The Netherlands Disclosures:
More informationVariability in drug response: towards more personalized diabetes care Petrykiv, Sergei
University of Groningen Variability in drug response: towards more personalized diabetes care Petrykiv, Sergei IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you
More informationThe albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients
Received: 5 February 217 Revised: 1 March 217 Accepted: 8 March 217 DOI: 1.1111/dom.12936 ORIGINAL ARTICLE The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual
More informationDapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin
University of Groningen Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving reninangiotensin blockers Heerspink, H. J. L.; Johnsson, E.; Gause-Nilsson, I.; Cain, V. A.;
More informationPaolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino
Paolo Fornengo SCDU Medicina Interna 3 AOU Città della Salute e della Scienza di Torino The KID-ney behind the curtain Altered Renal Glucose Control in Diabetes Gluconeogenesis is increased in postprandial
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationSGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective
SGLT2 Inhibitors: Town Hall Benefits vs Concerns: A renal perspective Matthew R. Weir, MD Professor and Chief Division of Nephrology University of Maryland School of Medicine Disclosure Slide Scientific
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meetings 1 st and 2 nd September 2016 - London and Leeds Prof Sunil
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationMonitoring of Renal Function in Heart Failure
Monitoring of Renal Function in Heart Failure Adriaan A. Voors, cardiologist The Netherlands Disclosures AAV received consultancy fees and/or research grants from: Alere, Bayer, Cardio3Biosciences, Celladon,
More informationSodium Glucose Cotransporter-2 Inhibition and Renal Function
Sodium Glucose Cotransporter-2 Inhibition and Renal Function by Harindra Rajasekeran A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Physiology
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.19 Subject: SGLT2 Inhibitors Page: 1 of 5 Last Review Date: December 3, 2015 SGLT2 Inhibitors Description
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationDiabetic Nephropathy Larry Lehrner, Ph.D.,M.D.
Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationTreatment of diabetic kidney disease: landmark studies and tribulations
Division of Nephrology, Department of Medicine, The University of Hong Kong Treatment of diabetic kidney disease: landmark studies and tribulations Sydney C.W. TANG APSN/JSN Continuing Medical Education
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationSGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS
SGLT-2 INHIBITORS: CVD REDUCTION THROUGH DIURESIS Dr. Kirtida Acharya National chair, Diabetes Kenya Consultant Endocrinologist/Diabetologist, MP Shah Hospital KCS Symposium, 30 th June, 2017 Sarova Whitesands,
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationManagement of New-Onset Proteinuria in the Ambulatory Care Setting. Akinlolu Ojo, MD, PhD, MBA
Management of New-Onset Proteinuria in the Ambulatory Care Setting Akinlolu Ojo, MD, PhD, MBA Urine dipstick results Negative Trace between 15 and 30 mg/dl 1+ between 30 and 100 mg/dl 2+ between 100 and
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationAn acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
original article http://www.kidney-international.org & 2011 International Society of Nephrology see commentary on page 235 An acute fall in estimated glomerular filtration rate during treatment with losartan
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More information6/10/2014. Chronic Kidney Disease - General management and standard of care. Management of CKD according to stage (KDOQI 2002)
Chronic Kidney Disease - General management and standard of care Dr Nathalie Demoulin, Prof Michel Jadoul Cliniques universitaires Saint-Luc Université Catholique de Louvain What should and can be done
More informationDiabetic Nephropathy
Diabetic Nephropathy Larry Lehrner, Ph.D.,M.D. llehrner@ksosn.com Commercial Support Acknowledgement: There is no outside support for this activity Financial Disclosure: stocks > 50,000 Bayer, J&J, Norvartis,Novo
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationIntroduction to the kidney: regulation of sodium & glucose. Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health
Introduction to the kidney: regulation of sodium & glucose Dr Nick Ashton Senior Lecturer in Renal Physiology Faculty of Biology, Medicine & Health Objectives Overview of kidney structure & function Glomerular
More informationUniversity of Groningen. Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste
University of Groningen Evaluation of renal end points in nephrology trials Weldegiorgis, Misghina Tekeste IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationSGLT2 Inhibitors. Vijay Negalur
C H A P T E R 173 SGLT2 Inhibitors Vijay Negalur INTRODUCTION Type 2 diabetes mellitus (T2DM) is a chronic progressive disease characterized by hyperglycemia that results from insulin resistance, diminished
More informationDr Brandon Orr-Walker
Dr Brandon Orr-Walker Endocrinologist Clinical Head of Endocrinology and Diabetes Middlemore Auckland 17:45-18:10 What Can New Agents Offer Us? Diabetes Management What do the new agents offer us? Brandon
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationFuture Clinical Impact to SGLT2i in the Treatment of Diabetes
Future Clinical Impact to SGLT2i in the Treatment of Diabetes Imam Subekti Division of Endocrinology and Metabolism, Department of Internal Medicine Ciptomangunkusumo Hospital / Faculty of Medicine, Universitas
More informationRenal effects of canagliflozin in type 2 diabetes mellitus
Current Medical Research and Opinion ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20 Renal effects of canagliflozin in type 2 diabetes mellitus Vlado
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationChronic Kidney Disease Management for Primary Care Physicians. Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015
Chronic Kidney Disease Management for Primary Care Physicians Dr. Allen Liu Consultant Nephrologist KTPH 21 November 2015 Singapore Renal Registry 2012 Incidence of Patients on Dialysis by Mode of Dialysis
More informationSPRINT: Consequences for CKD patients
SPRINT: Consequences for CKD patients 29 e Workshop Nierziekten Papendal 2018 December 12, 2018 MICHAEL ROCCO, MD, MSCE VARDAMAN M. BUCKALEW JR. PROFESSOR OF MEDICINE PROFESSOR OF PUBLIC HEALTH SCIENCES
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationFaculty. Disclosures. Learning Objectives. Definitions. Definitions (cont) The Role of the Kidney in Cardiometabolic Disease
Faculty The Role of the Kidney in Cardiometabolic Disease Christian W. Mende, MD, FACP, FACN, FASN, FASH Clinical Professor of Medicine University of California at San Diego San Diego, California Disclosures
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.19 Subject: SGLT2 Inhibitors Page: 1 of 6 Last Review Date: September 15, 2016 SGLT2 Inhibitors Description
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationHypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease
Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease July 2017 Indranil Dasgupta DM FRCP, Debasish Banerjee MD
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationRenal Blood flow; Renal Clearance. Dr Sitelbanat
Renal Blood flow; Renal Clearance Dr Sitelbanat Objectives At the end of this lecture student should be able to describe: Renal blood flow Autoregulation of GFR and RBF Regulation of GFR The Calcuation
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationAcute Kidney Injury. APSN JSN CME for Nephrology Trainees May Professor Robert Walker
Acute Kidney Injury APSN JSN CME for Nephrology Trainees May 2017 Professor Robert Walker Kidney International (2017) 91, 1033 1046; http://dx.doi.org/10.1016/ j.kint.2016.09.051 Case for discussion 55year
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBiomarkers, the Kidney and the Heart: Acute Kidney Injury
Biomarkers, the Kidney and the Heart: Acute Kidney Injury 12th Annual Conference on Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices San Diego May 13, 2016 Ravindra
More informationFarmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale
Farmaci innovativi e terapie di associazione: quali opportunità? Giuseppe Penno Dipartimento di Medicina Clinica e Sperimentale Dichiarazione esplicita di trasparenza delle fonti di finanziamento e dei
More informationMANAGEMENT OF DIABETIC PATIENTS WITH CKD. Roberto Pecoits-Filho, MD, PhD, FASN, FACP PUCPR, Curitiba, BRAZIL
MANAGEMENT OF DIABETIC PATIENTS WITH CKD Roberto Pecoits-Filho, MD, PhD, FASN, FACP PUCPR, Curitiba, BRAZIL Disclosure of Interests Honoraria Astra Zeneca, Novartis Trial participation and research grants
More informationMAJOR FUNCTIONS OF THE KIDNEY
MAJOR FUNCTIONS OF THE KIDNEY REGULATION OF BODY FLUID VOLUME REGULATION OF OSMOTIC BALANCE REGULATION OF ELECTROLYTE COMPOSITION REGULATION OF ACID-BASE BALANCE REGULATION OF BLOOD PRESSURE ERYTHROPOIESIS
More informationRenal safety of newer medications
Amar Puttanna MBChB, MRCP, Specialist Registrar, Department of Diabetes and Endocrinology, City Hospital, Birmingham, UK Lakshminarayanan Varadhan MBBS, MRCP (UK), MRCP Diabetes and Endocrinology, DipMedEd
More informationSodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
Editorial Page 1 of 5 Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes Hidekatsu Yanai Department of Internal Medicine, National Center for Global Health and Medicine
More informationDrugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events
Drugs to Treat Type 2 DM Demonstrate Reductions in Major Adverse Cardiovascular Events How does all this play out when it comes to treating patients with type 2 DM who have chronic kidney disease? Therapeutic
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDiabetic Nephropathy
Diabetic Nephropathy Objectives: Know what Diabetic Nephropathy means. Know how common is Diabetic nephropathy in Saudi Arabia and to appreciate how bad are this complications. Know the risk factors of
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationBASELINE CHARACTERISTICS OF THE STUDY POPULATION
COMPARISON OF TREATING METABOLIC ACIDOSIS IN CKD STAGE 4 HYPERTENSIVE KIDNEY DISEASE WITH FRUITS & VEGETABLES OR SODIUM BICARBONATE This was a 1-year, single-center, prospective, randomized, interventional
More informationSGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar
SGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar David Balis, MD University of Texas Southwestern Medical Center Internal Medicine Grand Rounds 10/6/17 This is to acknowledge that
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationRENAL PHYSIOLOGY. Physiology Unit 4
RENAL PHYSIOLOGY Physiology Unit 4 Renal Functions Primary Function is to regulate the chemistry of plasma through urine formation Additional Functions Regulate concentration of waste products Regulate
More informationSGLT2 Inhibitors From Discovery to Clinical Practice
SGLT2 Inhibitors From Discovery to Clinical Practice Sunder Mudaliar, MD, FRCP (Edin), FACP, FACE Clinical Professor of Medicine University of California, San Diego Staff Physician VA San Diego Healthcare
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationRenal Quiz - June 22, 21001
Renal Quiz - June 22, 21001 1. The molecular weight of calcium is 40 and chloride is 36. How many milligrams of CaCl 2 is required to give 2 meq of calcium? a) 40 b) 72 c) 112 d) 224 2. The extracellular
More informationSGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk
Managing Diabetes & CVD: Expling New Evidence & Opptunities ESC Congress, London, UK 30 August, 2015 SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk Silvio E. Inzucchi MD Yale
More informationDiabetes Update What s the fuss about CV Death?
Diabetes Update What s the fuss about CV Death? Peter J. Lin, MD, CCFP Director Primary Care Initiatives Canadian Heart Research Centre Associate Editor, Elsevier WebPortal Copyright 2017 by Sea Courses
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More information